Margaret Doyle

Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study

Ajay K. Nooka, Cesar Rodriguez, María‐Victoria Mateos et al. · Cancer · 2023 · 83 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +15

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

Kristine A. Frerichs, Christie P.M. Verkleij, María‐Victoria Mateos et al. · Blood Advances · 2023 · 78 citations · Full text

Life Sciences, Hematology, Immunology +17

Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma

Thomas G Martin, María‐Victoria Mateos, Ajay K. Nooka et al. · Cancer · 2023 · 62 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +15

FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL

Caroline Dartigeas, Borhane Slama, Margaret Doyle et al. · Clinical Hematology International · 2022 · 15 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies

Philippe Moreau, María-Victoria Mateos, Hartmut Goldschmidt et al. · Clinical Lymphoma Myeloma & Leukemia · 2025 · 10 citations · Full text

Medicine, Hematology, Oncology +17